The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents

Hyeon-Kyu Lee; Eun Bok Choi; Chwang Siek Pak
April 2009
Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p482
Academic Journal
Since the discovery of rimonabant (Acomplia: 1), a large effort has been directed at the discovery of new, potent and selective CB1R antagonists that serve as anti obesity drugs. As a result, a number of compounds reached various stages of clinical trials by late 2008. However, the announcement by Sanofi-Aventis that they were discontinuing all ongoing trials with rimonabant, as a result of the finding that risks associated with depression and anxiety outweighed its benefits, had a major impact on this area. A wave of terminations of programs targeting the development of CB1R blockers for treatment of obesity ensued. However, abandoning this CB1R therapeutic target for anti-obesity drug development seems to be premature, since there are a number of potential approaches have been uncovered to circumvent the problems of the current agents. In this review, we summarize advances that have been made and the status of studies of a diverse array of CB1R antagonists that have been identified mainly based on modifications of the first-in-class CB1R antagonist, rimonabant. Various approaches have been employed to design these analogs, such as bioisosteric replacement, introduction of conformational constraints, scaffold hopping and ligand-based molecular modeling. In addition, current approaches that have been uncovered to avoid psychiatric side effects of CB1R antagonists are summarized. Finally, the design of non-brain penetrating and peripherally acting CB1R antagonists, allosteric modulators of CB1R, and neutral antagonists for CB1R is also discussed in this review.


Related Articles


    The article focuses on a meta-analyis of rimonabant which revealed that the weight-loss drug increases the risk of depression and anxiety and can increase users' suicidal thoughts. The drug targets the endocannabinoid system of the brain, which helps trigger and reward food intake....

  • Disappointment at rimonabant halt.  // Independent Nurse;11/3/2008, p4 

    The article reports on clinicians' disappointment on the suspension of the weight-loss drug rimonabant, issued by the European Medicines Agency (EMEA). It is stated that EMEA raised concerns about the risk of psychiatric disorders in patients treated with the drug, and warned no further...

  • Suicide fears over weight-loss drug.  // PRWeek (London);7/4/2008, p6 

    The article looks at the suicide concerns over the weight-loss drug Acomplia, manufactured by Sanofi-Aventis. The drug has been approved by the British National Institute for Health and Clinical Excellence (NICE) and it is licensed in the Great Britain for the treatment of obese and overweight...

  • Sanofi-Aventis: near-term benign prostatic hyperplasia prospects look bleak.  // PharmaWatch: Monthly Review;Feb2010, Vol. 9 Issue 2, p17 

    In this article, the author discusses the Sanofi-Aventis SA's termination of its licensing agreement with AEterna Zentaris Inc. for the development of cetrorelix in benign prostatic hyperplasia (BPH) in the U.S. It mentions that the decision leaves the company with limited options to retain its...

  • Can a Pill Save You from Yourself? Hirshberg, Charles // Men's Health;Apr2006, Vol. 21 Issue 3, p140 

    This article provides information on the drug Acomplia. The drug could well be just the first of a whole new class of drugs that work by taking advantage of one of the most intriguing biological discoveries of the past 20 years, the endocannabinoid system. To study these sorts of effects,...

  • ORLISTAT.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p622 

    The article presents information on orlistat, an antiobesity drug and lipase inhibitor, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • The unrelenting fall of the pharmacological treatment of obesity. Di Dalmazi, Guido; Vicennati, Valentina; Pasquali, Renato; Pagotto, Uberto // Endocrine (1355008X);Dec2013, Vol. 44 Issue 3, p598 

    Nowadays pharmacological therapy to limit obesity has reached a critical stage: not only have Authorities limited the use of antiobesity drugs due to their proven inefficacy and dangerous side effects, but bariatric surgery has delivered better results. At present, when the number of obese...

  • Management: Part II--Drugs. Lean, Mike; Finer, Nick // BMJ: British Medical Journal (International Edition);10/14/2006, Vol. 331 Issue 7572, p794 

    The article offers a look at drug treatment for obesity. Although diet and exercise play the most important role in weight loss, effective drugs against obesity should reduce energy assimilation from food or stimulate energy expenditure. The article discusses weight loss, weight maintenance,...

  • orlistat. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p569 

    An encyclopedia entry for "orlistat" is presented. It refers to an anti-obesity drug used with a slimming diet for the treatment of severe obesity. It is different from appetite suppressants in that orlistat acts on the gastrointestinal tract, preventing the digestion of fats by lipases. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics